> Wyeth shareholders voted overwhelmingly to sell the drugmaker to Pfizer. Report
> Workers from Aspen Pharmacare Holdings are part of a multi-industry strike in South Africa over a pay dispute. Report
> Ranbaxy Laboratories got the nod from Canadian regulators to make and sell Ran-Amlodipine, a blood pressure and heart drug. Report
> Cambridge Major Laboratories will open its large-scale API manufacturing facility in Germantown, WI, July 30. Report
> Rotavirus vaccines made by Merck and GlaxoSmithKline may help stave off or lessen epidemics, a study has found. Report
> The market for rheumatoid arthritis drugs in Brazil will grow to more than $315 million by 2013, up from $200 million in 2008, Decision Resources predicts. Release
> Teva Pharmaceutical Industries announced that it had extended its agreement with Johnson & Johnson not to ship its version of Ortho Tri-Cyclen Lo. Release
> Mylan Pharmaceuticals got the FDA nod for additional strengths of its version of the antipsychotic drug Haloperidol. Mylan release
Biotech News
> Switzerland's Actelion says that positive mid-stage data on its experimental therapy for pulmonary arterial hypertension has spurred the developer to accelerate plans for late-stage clinical trials. Actelion says it will launch a Phase III trial of PGI2 by the end of the year. Report
> Shares of Human Genome Sciences spiked as high as 45 percent on speculation about upcoming late-stage data on its lupus drug Benlysta. And the gyrations in share price occurred despite some deep skepticism in the ranks of analysts. Report
> Facing a jury award of more than $36 million, Roanoke, VA-based Luna Innovations filed for bankruptcy protection today. The company is engaged in developing nanomedicines as well as sensing and instrumentation technology. Report
> With the world's first pandemic in more than four decades covering the globe, BioCryst took another step toward FDA approval for its flu therapy peramivir with the announcement that two late-stage trials proved positive in Japan. Report
> Forbes magazine makes the case that gaining an approval for denosumab is a 'must-win' for Amgen, which is being pressured by competing biosimilar bills in Congress. Report
> Less than 6 months after cutting back to 15 staffers, Ambrilia Biopharma announced that it had sold its experimental prostate cancer program--dubbed PCK3145--for $200,000 upfront and up to $15 million in milestones to Kotinos Pharmaceuticals. Report
And Finally... FDA may soon require improvements for the home glucose monitors used by more than 11 million diabetics in the United States. Report